Adma Biologics (ADMA) Equity Ratio (2011 - 2025)

Adma Biologics has reported Equity Ratio for 14 years, with the latest figure at 0.76 in Q4 2025.

• For the quarter ending Q4 2025, Equity Ratio rose 7.06% year-over-year to 0.76; the trailing twelve-month figure through Dec 2025 stood at 0.76 (up 7.06% YoY), and the FY2025 full-year result was 0.76, up 7.06% from the prior year.
• Equity Ratio for Q4 2025 stood at 0.76, up from 0.76 in the prior quarter.
• The five-year high for Equity Ratio was 0.76 in Q4 2025, with the low at 0.33 in Q3 2022.
• Historically, Equity Ratio has averaged 0.52 across 5 years, with a median of 0.46 in 2021.
• Annual changes were most pronounced in 2022 — Equity Ratio decreased 22.45% — and 2024, when it surged 73.89%.
• Adma Biologics' Equity Ratio stood at 0.51 in 2021, then decreased by 14.66% to 0.44 in 2022, then retreated by 5.82% to 0.41 in 2023, then surged by 73.89% to 0.71 in 2024, then advanced by 7.06% to 0.76 in 2025.
• The last three Equity Ratio figures came in at 0.76 (Q4 2025), 0.76 (Q3 2025), and 0.71 (Q2 2025), per Business Quant data.